Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

(2022) Anna Bateson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers

(2021) Hélène Thirot et al.   Antibiotics-Basel

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

(2020) Francesca Conradie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dosage regimen and toxicity risk assessment of linezolid in sepsis patients

(2020) Linjie Dou et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Universal regimens or universal access to drug susceptibility testing for tuberculosis?

(2019) Rebecca Acquah et al.   LANCET INFECTIOUS DISEASES

LINEZOLID INTERRUPTION IN PATIENTS WITH FLUOROQUINOLONE- RESISTANT TUBERCULOSIS RECEIVING A BEDAQUILINE-BASED TREATMENT REGIMEN

(2019) Olatunde Olayanju et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Management of drug-resistant tuberculosis

(2019) Christoph Lange et al.   LANCET

Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination

(2019) Esra Kaya Kılıç et al.   Journal of Infection in Developing Countries

Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index

(2016) Sean Wasserman et al.   Expert Review of Anti-Infective Therapy

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

(2015) Alexander S. Pym et al.   EUROPEAN RESPIRATORY JOURNAL

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

(2014) Keertan Dheda et al.   Lancet Respiratory Medicine

PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

(2008) R. Singh et al.   SCIENCE